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The efficient delivery of therapeutic molecules to the cartilage of joints is a major obstacle in developing useful therapeutic interventions;
hence, a targeted drug delivery system for this tissue is critical. We have overcome the challenge by developing a system that employs
electrostatic attraction between the negatively charged constituents of cartilage and a positively charged polymer, poly-beta amino esters
(PBAEs). We have demonstrated cartilage uptake of dexamethasone (DEX) covalently bound to the PBAE was doubled and retention in
tissues prolonged compared to the equivalent dose of the commercial drug formulation. Moreover, no adverse effects on chondrocytes were
found. Our data also show that PBAEs can bind not only healthy cartilage tissues but also enzymatically treated cartilage mimicking early
stages of OA. Our PBAEs-prodrug technology's advantages are fourfold; the specificity and efficacy of its targeting mechanism for cartilage,
the ease of its production and the low-cost nature of the delivery system.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/4.0/).
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load-bearing surfaces of synovial joints; they allow the synovial
joints' low friction and pain-free movements.1 The structure of
the extracellular matrix of cartilage is characterized by the
presence of glycosaminoglycans (GAGs). The resulting structure
is highly negatively charged allowing cartilage to perform the
required functions of shock absorber and low friction surface.
Osteoarthritis (OA) is the most common disease affecting
joint in the USA, with a reported 10% and 13% of male and
female population, respectively, over 60 years old experiencing
symptomatic OA,2 similar incidence was found also in the UK,3
with about 8.7 millions of patients.4 Some of the most common
predictors of OA are obesity and age5,6; therefore, the number of
OA diagnoses is expected to increase in light of the aging
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inflammation are offered; these can be through the administra-
tion of steroidal or non-steroidal anti-inflammatory drugs
(NSAID). Many of the drugs used to treat arthritis have serious
side effects, i.e. dexamethasone (DEX) has been linked to bone
loss, muscle weakness and atrophy, suppression of the adrenal
gland, increased risk of infections, peptic ulcer disease and growth
retardation.8 Moreover, drug penetration and retention in cartilage
is minimal.9 Hence, the development of a delivery system capable
of increasing the partitioning of steroids between the cartilage tissue
and synovial fluid would reduce the amount of drug dispersed, and
consequently, the incidence of side effects. Many different
approaches have been developed to improve intra-articular
treatment of joints i.e. PLGA10 and chitosan11 based microcro-
spheres; self-assembling nanoparticles,12 liposomes13 and calcito-
nin based nanocomplexes14 and polypeptides.7,15–17 However,
none of these approaches is ideal; therefore, new approaches are
needed to effectively tackle the problem.
Poly-beta amino esters (PBAEs) are a class of molecules
obtained from the co-polymerization of diacrylate and amine
molecules18; these molecules possess positive charges and are
biodegradable; they have been the subject of numerous
studies employing them as DNA delivery systems.19–24 Theticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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benefit of these compounds compared to other available
positively charged polymers (poly-cations) such as: poly-L-
lysine and polyethylenimine (PEI).19–24 The cytocompatibility
of PBAEs has also been demonstrated both in vitro25,26 and
in vivo.27,28
We hypothesize that positively charged PBAE (Figure 1, A).
could be employed as a drug delivery system to overcome the
challenge of delivering drugs to cartilage exploiting the
electrostatic attraction toward the negatively charged glycos-
aminoglycan (sGAG) components of the cartilage extracellular
matrix (Figure 1, A). The main objectives of this study were:
(a) to demonstrate the cartilage penetrating properties of PBAE;
(b) to determine uptake/retention enhancement in cartilage of
a OA model drug (DEX) when either covalently bound to
both ends of the PBAEs chains after functionalization or
electrostatically linked to the PBAE chain (mixing the drug
with PBAEs); (c) to establish efficacy in GAG depleted
cartilages representing OA and (d) to establish PBAE cytocom-
patibility toward chondrocytes.Figure 1. Pictorial schematization of the drug delivery mechanism developed
(A); structure of ionized PBAEs (B).Methods
A two-steps process was employed to synthesized end-
functionalized polymers. First, acrylate-terminated polymers
were prepared (Figure A1), then ethylenediamine was conjugat-
ed at both ends of the chains (Figure A2) in order to provide a
moiety for subsequent drug conjugation (Figure A4).Polymer synthesis
Piperazine or 4,4′-Trimethylenedipiperidine (Sigma, UK)
were used as amine monomers. Acrylate-terminated poly(β-
amino ester)s were synthesized by mixing 1,4 butanediol
diacrylate (Sigma, UK) and amine monomers in a 1.1:1 ratio
in Dichloro-methane (DCM) (Fischer, UK) at a concentration of
5 ml of DCM each 3.7 mmol of acrylate. The polymerization
was then performed under stirring at 50 °C for 48 h. PBAEs
were precipitated through pouring the reaction mixture in about
10 times the volume of diethyl-ether (Fischer, UK) under
vigorous mixing; the solvent was removed under vacuum.
Acrylate-terminated polymers were dissolved in DCM at a
concentration of 31.13% w/w; whilst ethylenediamine was
dissolved in DCM to a concentration of 0.25 mol/l. The capping
reaction (Figure A2) was performed by mixing the polymer/
DCM solution with ethylenediamine solution at a ratio of 800 μl
per 321 mg of polymer solution; the mixture was kept for 24 h at
room temperature under mixing.
End-capped PBAEs (amino terminated) were recovered
through precipitation in diethylether under vigorous mixing,
the unreacted amine were removed centrifuging the suspension
of PBAE in diethyl-ether for 2 min at 1155 g. The supernatant
was removed and the PBAEs washed twice with diethylether.
The amino end-capped PBAEs were then dried under vacuum.
PBAE made using piperazine and 4,4′-trimethylendipiper-
idine will be denoted as A1 and A2 through the text, respectively.Dexamethasone succinylation
Dexamethasone (DEX) was succinylated mixing 200 mg of
drug with 200 mg of succinic anhydride and 10 mg of
4-(Dimethylamino)pyridine (DMAP) in 50 ml Dimethyl-
formamide (DMF) (Figure A3). The reaction was performed
under nitrogen for 24 h at room temperature with mixing. The
solvent was removed under vacuum (in a rotary evaporator) and
the solid residue of succinylated Dexamethasone (DEX-succ)
was purified through repeated washing with dH2O. Finally, the
product was dried under vacuum.
Conjugation of DEX to PBAEs
The conjugation of DEX-succ was performed mixing 80 mg
of amine end-capped PBAE with 8 mg of succinylated drug,
8 mg of N,N′-Dicyclohexylcarbodiimide (DCC) and 8 mg of
N-hydroxysulfosuccinimide (NHS) in 25 ml of DCM (Figure
A4). Conjugates PBAEs-drug were precipitated through pouring
the reaction mixture in about 10 times the volume of
diethyl-ether under vigorous mixing; the solvent was removed
under vacuum. PBAEs-drug conjugates were washed twice with
diethyl-ether. The final product was then dried under vacuum.
PBAE characterization
Organic phase gel permeation chromatography (GPC) was
performed in a PL-GPC 20 (Polymer Laboratory) system
equipped with two ResiPore columns in series using THF as
Figure 2. Scheme of the transport chamber (A) and of the flow through the
cartilage sample (B).
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and columns were maintained at room temperature throughout
the runs. 100 μl of each sample prepared at 10 mg/ml in THF
were injected, and each sample was given 30 min to elute from
the column. The molecular weights (Mw and Mn) of the
polymers were reported relative to mono-disperse polystyrene
standards (EasiCal, Agilent).
PBAE sizes were measured using Dynamic Light Scattering
(DLS) using a Malvern Zetasizer Nano ZS (Malvern Instru-
ments, Malvern, U.K.); average electrophoretic motilities were
measured at 25 °C also using Malvern Zetasizer Nano ZS
(Malvern Instruments, Malvern, U.K.) and zeta potentials were
calculated using the Smoluchowsky model. For both analysis,
un-capped (acrylated terminated) PBAE were dissolved in
100 mM phosphate buffer (pH = 6.0) at about 20 mg/ml.
Cartilage samples
Bovine steers immature (7-day-old) feet were obtained from a
local abattoirs. Articular cartilage explants were surgically
removed under sterile conditions from metacarpo-phalangeal
joints. Full depth explants were excised using a 6 mm diameter
biopsy punches from the medial aspect of the medial condyle of
individual joints. Explants were placed initially in Dulbecco's
modified Eagles medium (DMEM; Invitrogen, Paisley, UK) and
washed in the same medium to remove blood and small
particulates due to the presence of a small amount of subchondral
bone lining the basal aspect of cartilage.
GAG depleted samples were obtained digesting the samples
in a solution of trypsin 1 mg/ml in PBS for 24 h at 37 °C and
washed three times in fresh PBS.
Cartilage GAG content quantification
The amount of GAG present in the cartilage samples before
and after depletion was determined through the DMMB
(Dimethyl-Methylene Blue) assay.29
DEX uptake into cartilage using PBAE-DEX
A PTFE transport chamber was designed and manufactured
to study one-way diffusion of solutes entering into cartilage
(Figure 2, A); the chamber walls were treated with casein to
block non-specific binding of solutes to PTFE surfaces. Cartilage
disks (6 mm diameter, ~0.4 mm thick) were cut in half, weighted
and placed in one of the holding slots machined into the
chamber. The chamber facing the superficial zone was filled with
50 μl of a known concentration of PBAEs-drug formulation in
PBS supplemented with protease inhibitors; the other chamber
side was filled with 50 μl of PBS containing protease inhibitors
alone. The chamber was then placed in a Petri dish containing
dH2O and covered to minimize evaporation then placed inside an
incubator at 37 °C; stagnant layers at cartilage surfaces were
prevented placing the dish on a slow-speed rocker. At required
intervals a sample was removed, washed in copious amount of
water and placed in an Eppendorf containing 1 ml of digestion
buffer. Experiments were performed on duplicate samples
originated from 3 different animals.
Comparison of the drug uptake was performed between a
solution of Dexamethasone phosphate (DEX-P) at the advisedconcentration of 4.4 mg/ml, equivalent to 4 mg/ml of DEX, and
a solution of PBAE-DEX containing the same amount of
steroidal drug.
Cartilage digestion
Cartilage samples were digested using a phosphate buffer
0.2 M at pH = 6.8 containing 300 mg/l of papain, EDTA 1 mM
and Dithiothreitol (DTT) 2 mM. Samples were placed in 1 ml of
the digestion buffer and incubated at 50 °C for 24 h.
DEX retention
Cartilage samples were exposed to the DEX solution in the
apparatus described above for 10 min and after washing in
copious amount of water, they were place in an Eppendorf
containing 0.5 ml of PBS. Samples were stored for up to 2.5 h at
37 °C, at fixed intervals the cartilage was removed from the PBS
solution, washed with water and placed in 1 ml of digestion
buffer.
DEX quantification
Dexamethasone in the digestion buffer was quantified
through reverse phase-HPLC. An Agilent series 1100 HPLC
system was equipped with a TeknoKroma TRACE EXCEL 120
ODSB 5 μm analytical column thermostated at 25 °C. The
injection volume was 25 μl, the mobile phase was PBS:acetoni-
trile:glacial acetic acid 70:26:4 with a flow rate of 1 ml/min and
the detector was a UV spectrophotometer at 244 nm. The
amount of drug present in the cartilage was then expressed as
mass of drug per cartilage mass.
Viability of chondrocytes after exposure to PBAE-DEX
The cartilage samples underwent a 1 h pre-digestion stage at
37 °C with 0.4% w/v pronase (Sigma, UK), dissolved in
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buff-
ered DMEM (Gibco, UK) supplemented with 50 U/50 μg/ml
penicillin–streptomycin (SigmaAldrich) and 2.5 mg/l amphotericin
B. Cartilage samples were placed in sterile Eppendorfs containing
the filter-sterilized enzyme solution by passage through a 0.22-μm
filter at a concentration of 1 ml solution for 5 cartilage extracts. The
cartilage fragmentswere thenwashed twicewith sterile PBS. 1ml of
collagenase II (Sigma, UK) 0.1% w/v solution was added to 5
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prepared in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES)-buffered DMEM (Gibco, UK) supplemented with 50 U/
50 μg/ml penicillin–streptomycin (Sigma Aldrich) and filter
sterilized. Samples were incubated for 16 h at 37 °C.
The triturate suspension was passed through a 100-mm nylon
cell strainer (Fisher, UK) to remove matrix debris, and added to
10 ml DMEM with GlutaMAX (DMEM/F-12) (Gibco, UK)
media, supplemented with 20% (v/v) FBS, 50 U/50 μg/ml
penicillin–streptomycin (Sigma Aldrich) and 2.5 mg/l ampho-
tericin B. Chondrocytes were centrifuged at 1500 rpm at 4 °C for
10 min to pellet the cells. The supernatant was discharged and
the pelleted cells were washed in sterile PBS. After centrifuga-
tion at 1500 rpm at 4 °C for 10 min, the cells were suspended in
supplemented 10 ml of DMEM/F-12 (10% FBS) and aseptically
transferred in cell culture flasks. Chondrocytes were cultured in a
humidified incubator at 37 °C and 5% CO2. After 3 days
chondrocytes were washed in sterile PBS and trypsinated. 24
well plates were inoculated with approximately 6000 cells/well
in 1 ml of DMEM/F-12 supplemented with 10% FBS and 1%
penicillin–streptomycin. Chondrocytes were grown for 2 days in
a humidified incubator at 37 °C and 5% CO2 before 15 μl of a
solution containing 4 mg/ml DEX was added. The DEX
solutions were prepared using either Dexamethasone phosphate
(DEX-P) or PBAE-DEX conjugates.
24 well plates were incubated in a humidified incubator at
37 °C and 5% CO2 for up to 3 days.
Chondrocytes viability was assessed through MTT and LDH
assay kits (Sigma, UK) according to manufacturer's protocols.
Experiments were performed in triplicate on cells originated
from 3 different animals.
Determination of diffusion coefficient of PBAE in cartilage
Amino terminated PBAEs were fluorescein-tagged (PBAE-
FITC) using FluoroTag™ FITC Conjugation Kit (Sigma, UK)
according to manufacturer's recommendations.
The diffusion coefficients of PBAE were determined using
the same PTFE transport chamber and arrangements described in
Figure 2. The chamber facing the superficial zone was filled with
50 μl of a known concentration of PBAEs-FITC supplemented
with protease inhibitors; the other chamber side was filled with
50 μl of PBS containing protease inhibitors alone. After
diffusion for a set length of time, 33 μl of liquid for both
chamber were removed and added to 67 μl of fresh PBS
contained in black 96 wells plate. Fluorescence was read using
FLUOstar OPTIMA Microplate Reader (BMG Labtech, UK)
with Ex =480 nm and Em = 520 nm. The parameters were set
assuring that the intensity response was in the linear range of
concentrations as determined during PBAE-FITC purification.
The ratio of fluorescence between the two sides of the
cartilage was plotted against diffusion time (t) and fitted with the
following equation using an in-house written FORTRAN code,
in order to identify the “break-through time” (tlag);
Ratio fluorescence
between cartilage sides
tð Þ ¼ t−tlag
  K tN tlag
0 tbtlag

ð1ÞWhere K is related to PBAE steady state flux. Then, the
diffusion coefficient (D) was calculated as30:
D ¼ δ
2
6 tlag
ð2Þ
where:
δ is the cartilage sample thickness.
Experiments were performed on triplicate samples originated
from 3 different animals (for a total of 9 measurements).
Fluorescent imaging of cartilage
Cartilage samples were removed from the perfusion chamber
after 1 min of exposure to FITC tagged PBAEs and rinsed in
PBS. The protocol employed to qualitatively assess the
penetration of PBAE in cartilages is shown in Figure A6; a
radial strip about 0.5 mm thick was cut from the cartilages half
disks exposing the middle section of the sample. The cartilage
sections were placed on a microscope glass slide and imaged
using a Leica DM, IRB microscope.
DEX release from PBAE-DEX
Release kinetics of DEX from PBAE-DEX were determined
using dialysis membranes (GE Healthcare Mini Dialysis Kits - 1
kDa cut-off). A solution of PBAE-DEX in PBS (4 mg of DEX/
ml) was placed in the Dialysis Kits and immersed in PBS and
incubated at 37 °C for up to 48 h under mixing; at prefixed
intervals the concentration of DEX released in the solution was
quantified.
The percent of DEX released from PBAE-DEX after a set
time (t) was calculated as:
DEX release tð Þ %½  ¼ conc:DEX tð Þ  Vol
mass DEX t ¼ 0ð Þ  100 ð3Þ
where:
conc. DEX is the concentration of DEX in the dialysis fluid;
Vol is the volume of the dialysis fluid;
mass DEX (t = 0) is the initial mass of DEX in PBAE-DEX.
DEX uptake into cartilage using DEX mixed with PBAE
A solution containing 4.4 mg/ml of Dexamethasone phos-
phate (equivalent to 4 mg/ml of Dexamethasone) and the same
quantity of pure end-capped PBAE that would be found in
PBAE-DEX was prepared and employed in the cartilage uptake
experiments previously described.
Statistical analysis
Chemical physical properties and diffusion coefficients of
PBAE date were compared using t test with a level of
significance of 0.05. Drug uptake, release and chondrocytes
viability were analyzed using one-way ANOVA to determine
any significant difference between the mean values, this was
followed by Tukey's post-hoc test (p b 0.05). Statistical analysis
was performed using SPSS.
Table 1
Mean and standard deviation of A1 and A2 chemical–physical properties.
PBAE Zeta pot. (mV) Size (nm) Mw (kDa) Mn (kDa)
A1 +11.60 ± 0.30 286 ± 63 12 ± 3 7 ± 3
A2 +8.94 ± 0.74 153 ± 36 13 ± 3 7 ± 3
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The characteristics of both A1 and A2 are reported in Table 1.
Both PBAE had a positive charge, +11.60 and +8.94 mV
respectively; A1 charge was statistically significantly higher than
A2 (p b 0.05). Examples of PBAE size distribution measured
through Dynamic Light Scattering (DLS) are shown in Figure
A7; the size of A1 in buffer pH = 6 was 286 nm and greater than
A2 (p b 0.05) that was 153 nm. No difference in both the
weighted average molecular mass (Mw) and the numerical
average molecular mass (Mn), estimated through GPC, was
noticed between A1 and A2 with values of 12 kDa for Mw and
7 kDa for Mn.
Exposure to trypsin resulted in a reduction of 54 ± 9% of the
GAG content of the cartilage samples.
Fluoro-tagging of PBAE with FITC revealed that PBAE were
able to penetrate the cartilage tissues used (Figure 3) in about 1 min;
it also appeared that A1 penetrates cartilage easier than A2 as little
fluorescent dye was noticed in the cartilage sample far from the
surface exposed to PBAE. The effective diffusion coefficient (DÞ
depends on the structure of the PBAE and is connected to the time
necessary to the PBAE to cross the full thickness of the sample (tlag)
as shown in (Figure 3); in cartilage samples with original level of
GAG, the diffusion coefficient for A1 (DA1Þwas greater than forA2
(DA2Þ (p b 0.05), 8 × 10−6 cm2/s and 5.5 × 10−6 cm2/s respec-
tively. Moreover, the diffusion coefficient in GAG depleted
cartilage for both PBAE was 1.3 × 10−5 cm2/s (p N 0.05) hence
greater than the corresponding diffusion coefficient in cartilagewith
normal levels of GAG.
When cartilage samples were exposed to the same concen-
tration of DEX, either as the commercial formulation of DEX-P
or in the conjugated form to PBAE, the amount of drug present in
the cartilage tissue (both normal and GAG depleted) increased
monotonically with time; furthermore after each time point,
conjugation of Dexamethasone to PBAE resulted in a higher
amount of the drug (p b 0.05) in the cartilage (Figure 4, A) even
after a very short period of time (1 min). The use of A2–1-DEX
resulted in the concentration of DEX in the cartilage to increase
only in the first minute and then remained almost constant
(p N 0.05). Despite relying on the electrostatic attraction
between the positive charges of PBAE and negative charges of
the GAG molecules to deliver the drug in the cartilage, PBAE
were also effective on GAG depleted cartilage (Figure 4, B) as
the amount of drug recovered in the tissues after exposure to
solutions of equal concentration of DEX was higher in case of
both PBAE-DEX tested than DEX-P (p b 0.05).
DEX retention in cartilages was poor as the great majority of
the drug was released from the cartilage in the first 30 min post
uptake (Figure 4), C and D; in normal GAG sample DEX
concentration fell below detection limit after 2.5 h (Figure 4, C)
in case of DEX-P; when A1-DEX were employed DEX was still
detectable in the cartilage even after 2.5 h, this was not the case
for A2-DEX as no drug was detected in the samples after 90 min
of release. In GAG depleted cartilage (Figure 4, D) the release of
DEX-P was quicker than for normal GAG samples as the drug
was not detected after 2.0 h when, furthermore the amount of
DEX remaining in the tissue delivered through A1-DEX or
A2-DEX was always higher than for DEX-P (p b 0.05).The viability of cartilage cells (chondrocytes) was not
affected after exposure to PBAE for at least 3 days (Figure 5).
Cell viability was assessed with two different protocols (LDH
and MTT) and both enzyme assays gave the same viability for
samples exposed to DEX-P and samples exposed to PBAE-DEX
(p N 0.05).
The ester bond conjugating DEX to both PBAE is almost
completely hydrolyzed over a period of 2 days (Figure 6), with
the majority of drug been released in the first few hours after
contact with aqueous solution. The kinetic of release from A2
appeared slightly slower than that from A1.
When pure PBAEs were present along with DEX, but the two
compounds were simply mixed together and not conjugated, the
uptake of DEX was always lower than the corresponding case of
pure steroidal drug DEX-P (Figure 7).Discussion
PBAEs are a class of polymers developed in the last two
decades almost exclusively for DNA delivery. The vast
application of PBAE to DNA delivery is based on the positive
charge of PBAE that allows them to bind the negatively charged
strands of DNA before entering the cells were the DNA is
released and the PBAE hydrolyzed into biocompatible
products.18–24 Effective and targeted delivery of drugs into
cartilage is notoriously difficult because of the blood vessels
absence and the tissue structure characterized by highly
concentrated negatively charged proteoglycans. We assumed
that PBAE positive charge could also be exploited for delivering
drugs into cartilages through the electrostatic interaction with the
proteoglycans and we demonstrated the feasibility of this
technology.
Both the molecular weights (Mw and Mn) and size of A1 and
A2 found (Table 1) are similar to values reported in literature for
poly-beta-amino-esters.31,32 Instead, zeta potentials (Table 1) are
lower than those reported for these polymers by Sunshine et al
(2012),31 a possible explanation for the higher potential in this
work is that their measurements were performed at pH = 5
instead of pH = 6 as used here; it is well known that fewer
nitrogen are protonated at higher pH and, therefore, the
polyelectrolyte exhibits lower zeta potential. This hypothesis is
also substantiated by the finding of Kim et al (2014)32 that
reported zeta potential of PBAE of about +13 mV when
measured in PBS. Moreover, the difference in zeta potential
observed between A1 and A2 can be attributed to the different
amines used in the polymeric chains (Figure 1, B) because
piperazine has pKb = 4.2 while piperidine has pKb = 2.9. The
size of the two polymers when in suspension does not depend
only on the chain length but also on the self-arrangement of the
Figure 3. Examples of Epifluorescent images of normal cartilages exposed to (A) A1-FITC and (B) A2-FITC for 1 min in the perfusion chamber with flow
direction marked by red arrows. Bar represent 150 μm. Non-equilibrium diffusive transport of PBAE-FITC across a 6 mm diameter, 400 μm thick normal (C)
and GAG depleted (D) cartilage explants, plotted as the ratio between measured downstream and upstream concentration vs. time. Symbols (● A1 ▼ A2) line
model fitting for tlag determination.
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solution through the protonation of the nitrogen.33
Counterions present in a solution mediate electrostatic
interactions between charged molecules through the formation
of electric double layers that screen the original charge present on
the molecule thus the higher the concentration of counterions the
lower the electrostatic forces; in order to account for this effect
we employed PBS solution that mimic the ionic strength of
biological fluids.
Trypsin is proteolic enzyme that is used to reduce the quantity
of GAG presents in cartilage and such its use mimics
osteoarthritis onset.7,35–38 The GAG reduction observed in our
samples (about 50%) was in line with the outcome of similar
treatments.38 The enzyme is dissolved in either PBS38 or
Na3PO4
7,36 and it has been suggested that the GAG depletion
outcome is independent from the choice of these solutions.39
In the delivery system presented in this work, PBAEs rely on
their electrostatic attraction toward the negatively charged GAG
to enhance drug uptake; therefore, a reduction in GAG could
have resulted in lower efficacy of the drug delivery system in
situations (cartilage affected by OA) when drugs are more likelyto be needed. Our results demonstrated that, despite the reduction
of GAG content, the uptake of DEX through PBAE-DEX was
greater than in case of cartilage with normal amount of GAG
(Figure 4). Similarly to these results, Elsaid et al (2013)40 found
that cartilage GAG depletion enhanced drug-loaded micelle
penetration into the tissues; Torzilli et al (1997)41 also reported
diffusion of insulin and dextran to be inversely proportional the
amount of proteoglycan cartilage content. Such phenomenon is
likely to depend on the reduced steric inherence exhibited by
GAG depleted cartilage to the penetration of PBAE as it has been
shown that GAG depleted tissues exhibit higher hydraulic
permeability35,36 than normal cartilage tissue. This hypothesis is
also confirmed by the higher diffusion coefficients of A1 and A2
in GAG depleted cartilage. Hence, PBAE is an effective drug
delivery system for cartilage even when the amount of GAG is
severely limited that more closely represent the situation when
treatment is required like in OA affected patients.
We utilized the ability of FITC to bind primary amines to
fluorescently tag the extremities of end-capped PBAEs as
ethylenediamine provided such moiety. Our results, using
PBAE tagged with FITC, provided evidence of PBAE
Figure 4. Comparison of DEX uptake in normal cartilage (A) and GAG depleted cartilage (B) using PBAE-DEX. Comparison of DEX retention in normal
cartilage (C) and GAG depleted cartilage (D) using PBAE-DEX after uptake for 10 min. Insets highlight behavior after long periods of drug release.■A1-DEX
▼ A2-DEX ◯ DEX-P.
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electrostatically bind to the surface of the cartilage (Figure 3).
The lower diffusion coefficient measured for A2 compared to A1
(Figure 3) was consistent with the images of cartilages obtained
using FITC tagged PBAE (Figure 3) and likely linked to the
different amine compounds present in the PBAE structure.
The size of the drug carrier directly impacts its cartilage
penetration ability41,42; it has been shown that the exclusion size
for avidin in cartilage is about 10 nm, 7 analogously Elsaid et al
(2013)40 gave evidence that 10 nm liposome were more
effective than 100 nm micelle in delivery drugs into cartilage.
The remarkable cartilage penetration ability exhibited by PBAE
is despite their relative large size, that is in the order of hundreds
of nanometers (Figure A6, Table 1); only few successful delivery
systems for cartilage have sizes comparable to PBAE.12,13
However, despite its pivotal role, size is not the only parameters
affecting cartilage penetration, for example charge7 and surface
modification40 have also been implicated in regulating cartilage
diffusion. Our results also highlight the likely impact of thepolymer structure as A2–1 is smaller than A1–1 but returns
worst uptake and retention performance (Figure 4).
The release kinetic of DEX from PBAE-DEX (Figure 6) is
dependent on the hydrolysis of the ester bond linking the
steroidal drug to PBAE (Figure A4); the kinetic of hydrolysis is
comparable to that of DEX-avidin17 or HPMA34 when an
ester bond is used to conjugate polymer and drug, importantly
for the efficiency of the delivery system the hydrolysis
appears complete (Figure 6) thus freeing all drug molecules
loaded to PBAE. In this context, our results seem to suggest
the critical role played by the type of bond used to conjugate
polymer and drug over the type of polymer. It is has also
been shown that DEX conjugation through a hydrazone,
instead of an ester bond, results in a slower kinetics of drug
release17,34; consequently allowing the possibility of engineering
slow and fast release systems. Nevertheless, when steroids are
entrapped in hydrophobic system (micelle or liposome) the
release is generally ineffective with the majority of drug
remaining entrapped.34
Figure 5. Viability of chondrocytes exposed to DEX-P (black columns),
A1-DEX (gray columns) and A2- DEX (white columns) assessed through
MTT (A) and (LDH) assay.
Figure 6. In vitro DEX release profile from PBAE-DEX. ● A1-DEX ▼
A2-DEX.
546 S. Perni, P. Prokopovich / Nanomedicine: Nanotechnology, Biology, and Medicine 13 (2017) 539–548The half-life of drugs in joint is about few hours,9,43 thus
“wash out” from cartilage is known to reduce treatment efficacy.
For this reason it is important that a new delivery system for
cartilage not only improves uptake but also retention7,9; we have
shown that DEX could be retained in cartilage through the use of
PBAE-DEX for longer periods of time than when a commercial
DEX phosphate solution is used (Figure 4). Because the cleavage
of DEX from PBAE-DEX occurred in few hours, our drug
retention results are likely to depend on the hydrolysis reaction
kinetic; the possibility of tuning the pace of drug release through
a different conjugation bond would allow enhancing retention
further.
Viability of chondrocytes was determined using two
independent enzyme assays; MTT is based on mitochondrial
activity whilst LDH is based on the relative concentration of
lactate dehydrogenase in the media and inside the cells. We
chose to use two tests as single assay could be inconclusive; for
example a reduced metabolic activity could be interpreted as a
reduction of viable cells if only MTT was employed.44,45 Both
tests revealed that chondrocytes were not affected by thepresence of PBAE in the media (Figure 5) such providing
essential information for future medical applications of the drug
delivery system proposed in this work. This result was expected
as PBAEs are known to be cytocompatible (a consequence of the
easy hydrolyzation and biological compatibility of the degrada-
tion products) but gathering such experimental evidence was
critical; as chondrocytes had not been exposed to PBAE yet.
Moreover, our data clearly demonstrate that conjugation between
DEX and PBAE is essential for enhancing drug uptake in
cartilage (Figure 7).
One of the greatest advantages of PBAE over other molecules
such as avidin is their relative low cost resulting from
inexpensive monomers and ease of preparation, additionally
the diffusion coefficient of PBAE in cartilages are 2–3 folds
greater than avidin.7 Despite the large amount of research carried
out with PBAE, our work is the first demonstrating their efficacy
in augmenting drug uptake in cartilage and also the first where a
drug is directly linked to the polymer chain.
We demonstrated, using DEX as a model drug, that PBAE
constitute an effective drug delivery system for cartilage based
on the electrostatic attraction between GAG and PBAE. We
employed two strategies to link DEX to PBAE, one was to form a
covalent bond between drug and carrier and another was to
electrostatically bind the two; our results revealed that the
covalent bond was essential to achieve the goal of developing a
targeted drug delivery system for cartilage. In GAG depleted
samples, resembling early stage of OA, the reduced driving force
for the PBAE penetration did not hinder the efficacy of the
delivery system; on the contrary the efficacy is enhanced likely
in virtue of the higher hydraulic permeability of such cartilage
tissue. The improved targeted delivery and retention of the
chosen drug to cartilage has the benefit of improving efficiency
as a lower amount of drug will be needed to achieve the same
concentration in the tissue; particularly for mono-articular
diseases where intra-articular injection is a common therapeutic
approach. We, therefore, foresee OA treatments based on PBAE
to boost drug uptake and retention in cartilage, simultaneously
reducing drug off-site effects in virtue of the specificity and
Figure 7. Comparison of DEX uptake in normal cartilage using PBAE mixed
with DEX-P. ■ A1-DEX ▼ A2-DEX ◯ DEX-P.
547S. Perni, P. Prokopovich / Nanomedicine: Nanotechnology, Biology, and Medicine 13 (2017) 539–548efficacy of its targeting mechanism and the overall cost of the
treatment as PBAEs are inexpensive.
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